Sutro Biopharma (STRO) revenue and earnings history
Sutro Biopharma reported revenue of $102M for fiscal 2025 (year ended Dec 31, 2025), +65.2% on the year before, and net income of −$191M.
Over 9 years, from fiscal 2016 to fiscal 2025, revenue grew at a compound rate of +6.2% a year.
Revenue and net income, 10 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $102M+65.2% | −$158M | −$191M | −$177M | — | — | $14M | — | — | $58.1M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Sutro Biopharma (STRO) on OQRO.
Common questions
What was Sutro Biopharma's revenue in fiscal 2025?
$102M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 23, 2026. That is +65.2% on fiscal 2024 ($62M).
How fast has Sutro Biopharma's revenue grown?
From $59.7M in fiscal 2016 to $102M in fiscal 2025: a compound annual growth rate of +6.2% over 9 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Sutro Biopharma been profitable?
It reported a net loss in 9 of the years shown (2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was $1.7M in fiscal 2016.
Where these figures come from
The SEC’s companyfacts data: every figure Sutro Biopharma tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
